Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been given a consensus rating of “Moderate Buy” by the eight research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $20.40.

TLX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. Citigroup dropped their price target on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Royal Bank Of Canada cut Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, July 6th.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors have recently made changes to their positions in TLX. Russell Investments Group Ltd. purchased a new position in shares of Telix Pharmaceuticals in the second quarter worth approximately $975,000. Jane Street Group LLC purchased a new stake in Telix Pharmaceuticals during the second quarter valued at approximately $564,000. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals in the second quarter worth approximately $213,000. Rhumbline Advisers raised its position in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the period. Finally, JPMorgan Chase & Co. purchased a new position in shares of Telix Pharmaceuticals during the 3rd quarter worth $243,000.

Telix Pharmaceuticals Trading Up 3.0%

Shares of Telix Pharmaceuticals stock opened at $12.33 on Friday. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $12.60. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The company’s 50 day moving average is $10.67 and its 200 day moving average is $9.49.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.